You Hailong, Yang Bin, Liu Huifang, Wu Wencai, Yu Fei, Lin Nan, Yang WenJiao, Hu Bingxue, Liu Yong, Zou Hongyan, Hao Sijia, Xiao Yunping, Xu Teng, Jiang Yanfang
Genetic Diagnosis Center, The First Hospital of Jilin University, Changchun, Jilin, People's Republic of China.
Center for Infectious Diseases, Vision Medicals Co., Ltd, Guangzhou, Guangdong, People's Republic of China.
Emerg Microbes Infect. 2025 Dec;14(1):2449087. doi: 10.1080/22221751.2024.2449087. Epub 2025 Jan 13.
To unravel distinct patterns of metagenomic surveillance and respiratory microbiota between () P1-1 and P1-2 and to explore the impact of the COVID-19 pandemic on epidemiological features, we conducted a multicentre retrospective study which spanned 90,886 pneumonia patients, among which 3164 cases were identified. Our findings revealed a concurrent outbreak of , with the positivity rate rising sharply to 9.62% from July 2023, compared to the 0.16% to 4.06% positivity rate observed during the 2020-2022 COVID-19 pandemic. P1-1 had a higher odds ratio of co-detecting opportunistic pathogens. However, no significant differences were observed in the co-detection odds ratio between children and other age groups in P1-2. This study is the first to demonstrate differences in relative abundance, diversity of respiratory microbiota and co-detection rate of opportunistic pathogen between P1-1 and P1-2. Through bronchoalveolar lavage (BAL) metagenomic and host transcriptomic analyses, we identified variations in co-detection rates of P1-1 genotype with opportunistic pathogens like , alterations in respiratory microbiota composition, lung inflammation, and disruption of ciliary function. Consistent with the results of host transcriptome, we found that P1-1 infections were associated with significantly higher rates of requiring respiratory support and mechanical ventilation compared to P1-2 infections (Fisher's exact test, -value = 0.035/0.004). Our study provides preliminary evidence of clinical severity between strains, underscoring the need for ongoing research and development of targeted therapeutic strategies.
为了揭示P1-1和P1-2之间宏基因组监测和呼吸道微生物群的不同模式,并探讨新冠疫情对流行病学特征的影响,我们开展了一项多中心回顾性研究,涵盖90886例肺炎患者,其中确诊3164例。我们的研究结果显示,[病原体名称]同时爆发,阳性率从2023年7月起急剧上升至9.62%,而在2020 - 2022年新冠疫情期间观察到的阳性率为0.16%至4.06%。P1-1共检测到机会性病原体的比值比更高。然而,在P1-2中,儿童与其他年龄组之间的共检测比值比未观察到显著差异。本研究首次证明了P1-1和P1-2在呼吸道微生物群的相对丰度、多样性以及机会性病原体共检测率方面存在差异。通过支气管肺泡灌洗(BAL)宏基因组和宿主转录组分析,我们确定了P1-1基因型与[机会性病原体名称]等机会性病原体的共检测率变化、呼吸道微生物群组成改变、肺部炎症以及纤毛功能破坏。与宿主转录组结果一致,我们发现与P1-2感染相比,P1-1感染需要呼吸支持和机械通气的比例显著更高(Fisher精确检验,P值 = 0.035/0.004)。我们的研究提供了[病原体名称]菌株之间临床严重程度的初步证据,强调了持续研发针对性治疗策略的必要性。